GSK enters exclusive license agreement with Hansoh for HS-20093 | GSK
GSK and Hansoh Pharma announced an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug conjugate, showing promising clinical activity in lung cancer. GSK gains worldwide rights (excluding China) for development and commercialization, with Hansoh eligible for up to $1.525 billion in milestones and royalties. HS-20093 is in phase I/II trials in China, with GSK planning phase I trials outside China in 2024.
Related Clinical Trials
Reference News
GSK and Hansoh Pharma announced an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug conjugate, showing promising clinical activity in lung cancer. GSK gains worldwide rights (excluding China) for development and commercialization, with Hansoh eligible for up to $1.525 billion in milestones and royalties. HS-20093 is in phase I/II trials in China, with GSK planning phase I trials outside China in 2024.